Drug Profile
Research programme: EGFR/HER2 inhibitors - Array BioPharma
Latest Information Update: 02 Aug 2019
Price :
$50
*
At a glance
- Originator Array BioPharma
- Class
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 30 Jul 2019 Array Biopharma has been acquired by Pfizer
- 10 Aug 2011 No development reported - Preclinical for Cancer in USA (PO)
- 08 Aug 2005 Array BioPharma has filed an IND with the FDA in the USA for cancer